-
Posted by
Two Blokes May 20, 2025 -
Filed in
Stock
-
12 views
Shares of gene therapy specialist, CRISPR Therapeutics (CRSP -0.34%) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first treatment from the Food and Drug Administration (FDA), but the stock price is way down.
